Low-dose radiation inferior to standard-dose radiation in children with medulloblastoma


A Children’s Oncology Group (COG) study has evaluated the impact of low-dose radiation therapy in children with medulloblastoma.

Standard therapy for patients with medulloblastoma aged >3 years consists of craniospinal radiation (CSRT) plus chemotherapy. However, this approach is associated with radiation-related neurocognitive decline and poor quality of life.

The COG trial was conducted in part to determine whether lower doses of CSRT would reduce neurocognitive decline without compromising event-free survival (EFS) and overall survival (OS).

A total of 226 patients aged 3 to 7 years were randomized to low-dose CSRT (18.0 Gy) or standard-dose CSRT (23.4 Gy). In a post-hoc analysis, the impact of molecular subtype (WNT, SHH, Group 3, or Group 4) on survival outcomes was also assessed.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.